<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552227</url>
  </required_header>
  <id_info>
    <org_study_id>6038</org_study_id>
    <secondary_id>B7A-MC-MBCZ</secondary_id>
    <nct_id>NCT00552227</nct_id>
  </id_info>
  <brief_title>Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effect of Protein Kinase C (PKC) β Specific Inhibitor on Oxidant Stress in Patient With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chromaderm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chromaderm, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel&#xD;
      inflammation associated with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measure is the ratio of urinary isoprostane to creatinine as measured by gas chromatography/mass spectrometry (GC/MS) in the two consecutive 12-hour urine samples obtained prior to both Visit 2 (baseline) and Visit 3 (endpoint).</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in brachial artery diameter induced by reactive hyperemia as measured by ultrasound (flow-mediated dilatation) at Visits 2 and 3.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of urinary albumin to creatinine</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruboxistaurin</intervention_name>
    <description>oral 32 mg daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LY333531</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetes mellitus&#xD;
&#xD;
          2. ≥35 years of age&#xD;
&#xD;
          3. Fasting low-density lipoprotein (LDL) cholesterol &lt;160 mg/dL, triglycerides (TG) &lt;400&#xD;
             mg/dL&#xD;
&#xD;
          4. Sitting systolic blood pressure &lt;160 mm Hg and sitting diastolic blood pressure &lt;90 mm&#xD;
             Hg as determined by the mean of three separate measurements.&#xD;
&#xD;
          5. Hemoglobin A1c (HbA1c) ≥7% and ≤11%.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          6. A serum creatinine &gt;2.0 mg/dL or who have received a renal transplant or are currently&#xD;
             being treated with dialysis.&#xD;
&#xD;
          7. Alanine aminotransaminase (ALT), alkaline phosphatase (ALP), or total bilirubin (TB)&#xD;
             greater than two times the upper limit of normal&#xD;
&#xD;
          8. Current use of aspirin, nitroglycerin or long-acting nitrates or potential need for&#xD;
             use of aspirin, nitroglycerin or long-acting nitrates to treat documented&#xD;
             cerebrovascular or coronary artery disease during the study.&#xD;
&#xD;
          9. Use of tobacco products (for example, cigarettes, cigars, pipes, and snuff) within the&#xD;
             6 months prior to Visit 1.&#xD;
&#xD;
         10. Requirement for treatment with very potent inhibitors of cytochrome P450 3A4 or&#xD;
             inhibitors of cytochrome P450 2D6.&#xD;
&#xD;
         11. Requirement for treatment with inducers of cytochrome P450 3A4.&#xD;
&#xD;
         12. Active infection/inflammation as determined by body temperature &gt;38°C OR current use&#xD;
             of systemic antibacterial, antifungal, or antiviral medication OR active chronic&#xD;
             inflammation (for example, lupus, rheumatoid arthritis, multiple sclerosis).&#xD;
&#xD;
         13. Abdominal, thoracic, vascular, or cranial surgery that is determined to be of major&#xD;
             significance by the investigator within 3 months prior to Visit 1.&#xD;
&#xD;
         14. Current suspicion of carcinoma or treatment for cancer within 6 months prior to Visit&#xD;
             1 or anticipated treatment for cancer during the course of the study, with the&#xD;
             exception of superficial lesions such as basal cell carcinoma and squamous cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
         15. Patients who have taken any non-steroidal anti-inflammatory agents (including aspirin&#xD;
             and cyclooxygenase-2 inhibitors) or vitamins within 14 days of entry (Visit 1).&#xD;
&#xD;
         16. Patients who have previously completed or withdrawn from this study or any other study&#xD;
             investigating LY333531 (unless the patient is being re-screened 14 days or more after&#xD;
             discontinuing the use of vitamins or non-steroidal anti-inflammatory agents.&#xD;
&#xD;
         17. Directly affiliated with the conduct of this study, or are immediate family of someone&#xD;
             directly affiliated with the conduct of this study (that is, Lilly employees,&#xD;
             investigators, site personnel, or their immediate families). Immediate family is&#xD;
             defined as a spouse, parent, child, or sibling, whether biological or legally adopted.&#xD;
&#xD;
         18. Treatment with an investigational drug within the last 30 days at the time of study&#xD;
             entry.&#xD;
&#xD;
         19. Females of child-bearing potential (not surgically sterilized and between menarche and&#xD;
             &lt;5 years post menopause) who test positive for pregnancy at the time of enrollment&#xD;
             based on a serum pregnancy test or who intend to become pregnant during the study.&#xD;
&#xD;
         20. Females of child-bearing potential who do not agree to use a reliable method of birth&#xD;
             control (for example, use of oral contraceptives or Norplant®; a reliable barrier&#xD;
             method of birth control [diaphragms with contraceptive jelly; cervical caps with&#xD;
             contraceptive jelly; condoms with contraceptive foam; intrauterine devices]; partner&#xD;
             with vasectomy; or abstinence) during the study.&#xD;
&#xD;
         21. A female who is breast-feeding.&#xD;
&#xD;
         22. Any other findings, in the opinion of the investigator, that would preclude the&#xD;
             patient's participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muredach Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania, Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ruboxistaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

